Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 7

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 7
---
 as alternatives to traditional antibiotics, providing a potential method of treating
patients suffering from drug-resistant and difficult-to-treat bacterial infections. To date, we have completed three critical Phase 2
trials, utilizing two distinct phage cocktails against two different bacterial pathogens with the potential to treat chronic pulmonary
disease complicated by bacterial infection, as well as acute systemic bacterial infection. We believe that we are uniquely advancing our
two lead candidates, referred to as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections.

<div align='center'>S-5</div>

Pseudomonas aeruginosa Phage Product Candidate, AP-PA02

Clinical Development of AP-PA02 in Cystic Fibrosis: Completed Phase 1b/2a Study

Our first phage candidate, inhaled AP-PA02, is
focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa (“P. aeruginosa”).
On October 14, 2020, we received the approval to proceed from the U.S. Food and Drug Administration (the “FDA”) for our
Investigational New Drug (“IND”) application for AP-PA02. In the first quarter of 2023, we announced positive topline results
from the completed “SWARM-P.a.” study – a Phase 1b/2a, multicenter, double-blind, randomized, placebo-controlled,
single ascending dose and multiple ascending dose clinical trial to evaluate the safety and tolerability of inhaled AP-PA02 in subjects
with cystic fibrosis (“CF”) and chronic pulmonary P. aeruginosainfection. Data indicate that AP-PA02 was
well-tolerated with a treatment emergent adverse event profile similar to placebo. Pharmacokinetics findings confirm that AP-PA02 can
be effectively delivered to the lungs through nebulization with minimal systemic exposure, with single ascending doses and multiple ascending
doses resulting in a proportional increase in exposure as measured in induced sputum. AP-PA02 exposures were generally consistent across
subjects. Additionally, bacterial levels of P. aeruginosain the sputum measured at several timepoints suggest improvement
in bacterial load reduction for subjects treated with AP-PA02 at the end of treatment as compared to placebo after ten days of dosing.
In addition, a correlation was seen between increasing phage dose (higher AP-PA02 exposures) and reduction in the bacterial load, supporting
the bi